Hemostats Market by Type (Collagen-Based Hemostats, Combination Hemostats, Gelatin-Based Hemostats), Formulation (Matrix & Gel Hemostats, Powder Hemostats, Sheet & Pad Hemostats), Application - Global Forecast 2024-2030

[192 Pages Report] The Hemostats Market size was estimated at USD 3.23 billion in 2023 and expected to reach USD 3.42 billion in 2024, at a CAGR 5.65% to reach USD 4.75 billion by 2030.

The hemostats are a range of medical devices and products designed to control, prevent, and stop bleeding during surgical procedures and traumatic injuries. These devices play an important role in managing blood loss and facilitate proper tissue healing while reducing the risk of complications. Hemostats have applications in numerous surgical specialties, including cardiovascular surgery, general surgery, orthopedic surgery, neurosurgery, gynecologic surgery, and dental surgery. The growing occurrence of chronic diseases among an aging population drives the demand for surgeries that necessitate effective blood loss management solutions, consequently expanding the utilization of diverse hemostatic agents. Additionally, increasing inclination toward minimally invasive procedures with rising investments by government bodies and healthcare organizations to improve surgical infrastructure is raising the usage of hemostats. High R&D costs associated with developing breakthrough products and a high risk of contamination with hemostats hamper market growth. The increasing development of biologically compatible hemostats by market vendors that minimize adverse effects while providing effective bleeding control is expected to create opportunities for market growth.

Collagen-based hemostats are derived from purified collagen; they are known for their excellent biocompatibility and ability to accelerate clot formation by initiating platelet aggregation. These hemostats are often preferred in surgeries involving soft tissues and delicate structures, such as neurosurgery and ophthalmic surgery. Combination hemostats consist of two or more active agents that work synergistically to enhance hemostatic efficacy. They typically combine the benefits of hemostats, such as collagen-based, gelatin-based, and thrombin-based products. The demand for combination hemostats is growing due to their increased effectiveness in minimizing bleeding complications during complex surgical procedures. Oxidized regenerated cellulose-based hemostats are made from plant-derived cellulose that undergoes oxidation and regeneration processes. They possess antimicrobial properties and effectively control bleeding by creating a physical barrier between blood vessels and surrounding tissues. ORC-based hemostats are often used in dental surgeries, gastrointestinal surgeries, and gynecological procedures. Thrombin-based hemostats contain human or bovine thrombin as their active ingredient, which activates the coagulation cascade, resulting in rapid clot formation. They are particularly useful in controlling bleeding where traditional techniques may be ineffective or impractical, such as cardiovascular surgeries or organ transplantations. The collagen-based hemostats provide excellent biocompatibility and are often preferred for delicate surgeries. Combination hemostats offer increased effectiveness due to their synergistic properties. Gelatin-based hemostats are valued for their rapid blood clotting ability in critical situations. ORC-based hemostats exhibit antimicrobial properties and create a physical barrier for bleeding control, while thrombin-based hemostats activate the coagulation cascade for rapid clot formation.

Matrix and gel hemostats are biocompatible, absorbable materials that facilitate rapid clot formation. They are preferred in situations where the application of direct pressure during surgery is difficult, such as in minimally invasive procedures. Powder hemostats work by absorbing fluid from bleeding tissue and enhancing platelet aggregation. Their ease of application makes them suitable for various surgical specialties, including general, orthopedic, cardiovascular, and neurosurgery. Sheet and pad hemostats are flexible bioabsorbable materials, allowing for better conformity to irregular wound surfaces. They are utilized in surgeries where larger areas need to be covered, and suturing is challenging. Sponge hemostats are highly absorbent materials easily molded into various shapes, making them suitable for irregular wound cavities. They are commonly used in dental and oral surgeries, as well as neurosurgery and cardiovascular surgery. Matrix & gel hemostats provide rapid clot formation in hard-to-reach areas, whereas powder hemostats offer easy application across surgical specialties. Sheet & pad hemostats conform to irregular wound surfaces covering larger areas; then, sponge hemostats provide excellent absorbency and moldability for irregular wound cavities.

Cardiovascular surgeries involve high blood flow, arteries, and veins, often requiring efficient hemostatic solutions to prevent excessive bleeding. Hemostats are widely preferred in these procedures due to their rapid action and ability to achieve effective hemostasis. In general surgery, the use of hemostats plays a significant role in wound management and ensuring minimum blood loss during procedures such as appendectomy and hernia repair. Gynecological surgeries often require meticulous control of bleeding during delicate procedures such as hysterectomy and myomectomy. Hemostats have effectively minimized adhesions while providing adequate hemostasis during these surgeries. Hemostats are specifically designed to address this need while preserving neural structures. Orthopedic surgeries, including joint replacements and fracture fixation, require robust hemostatic agents as they involve cutting through dense bone and connective tissues. In reconstructive surgery, which includes skin grafting and flap reconstruction, managing blood loss becomes critical for successful outcomes. Hemostatic agents are preferred in these cases due to their adaptability across different tissues and ability to seal large wounds effectively. Compared to other applications, cardiovascular surgeries show a higher need-based preference for advanced hemostatic agents.

The growing number of surgical procedures with the rising availability of advanced healthcare facilities, especially across the U.S., Canada, and Brazil, are expanding the growth of the hemostats market in the Americas. According to the American Society of Plastic Surgeons, in 2022, a total of 1,017,003 reconstructive surgeries were performed, necessitating the use of hemostats. The emerging trend of medical tourism across Canada, Dubai, Singapore, Japan, and the UK is expanding the number of minimally invasive surgical procedures, thereby creating a platform for the hemostats market. According to the Medical Tourism Index survey (MTA), Canada is one of the preferred destinations, attracting around 14 million Americans from other nations. Ongoing advancements in healthcare infrastructure and technologies across European countries, with constant support from regulatory bodies such as the European Medicines Agency (EMA) on expanding the manufacturing of medical devices and healthcare infrastructure, are bolstering the European market. The Middle East & Africa region presents promising growth opportunities due to increasing healthcare expenditure and government initiatives towards modernizing healthcare infrastructure. Countries, including Saudi Arabia, the United Arab Emirates, and South Africa, are witnessing a surge in the need for effective hemostatic solutions with the rising number of surgical interventions. Moreover, increased government funding to expand the manufacturing of medical devices domestically across India, Australia, China, and Japan and increased awareness associated with minimally invasive surgeries are expected to bolster market growth in Asia-Pacific.

The FPNV Positioning Matrix is pivotal in evaluating the Hemostats Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Hemostats Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

• Teleflex Receives FDA Clearance for Expanded Indication for QuikClot Control+ Hemostatic Device Usage in Cardiac Surgical Procedures

  Teleflex Incorporated received clearance from the U.S. Food and Drug Administration (FDA) for the QuikClot Control+ Hemostatic Device. This device is now approved for use in cardiac surgical procedures to address mild and moderate bleeding, as well as bone surface bleeding after a sternotomy. [Published On: 2023-08-01]

• Baxter Launches PERCLOT Absorbable Hemostatic Powder

  Baxter International Inc. introduced PERCLOT Absorbable Hemostatic Powder in the U.S., a passive hemostatic powder designed for patients with intact coagulation. PERCLOT's granules effectively absorb water, forming a gelled adhesive matrix that acts as a mechanical barrier against further bleeding. This process promotes the accumulation of platelets, red blood cells, and coagulation proteins, aiding in the hemostatic process. [Published On: 2023-07-24]

• Artivion Gains FDA Approval for PerClot, Starts Transfer to Baxter

  Artivion, Inc. has received FDA premarket application approval for its absorbable hemostatic system, PerClot. In July 2021, Baxter acquired full ownership of PerClot through a sale agreement. The FDA approval of PerClot, Artivion represents a significant step ahead in optimizing patient care by addressing intraoperative bleeding. [Published On: 2023-05-24]

The report delves into recent significant developments in the Hemostats Market, highlighting leading vendors and their innovative profiles. These include A.R. Medicom, Inc., ACTEON Group, Advamedica Inc., Advanced Medical Solutions Group PLC, Advin Health Care, Aegis Lifesciences Private Limited, Argon Medical Devices, B. Braun SE, Baxter International Inc., Becton, Dickinson and Company, Betatech Medical, Convatec Group PLC, Cook Group Incorporated, Cortis Medtech Pvt Ltd, Cotran Corporation, Dolphin Sutures by Futura Surgicare Pvt. Ltd., Dynarex Corporation, Gelita AG, Hangzhou Singclean Medical Products Co.,Ltd., Healthium Medtech Ltd, Hemostasis, LLC, Integra LifeSciences Holdings Corporation, Johnson & Johnson Services, Inc., Medcura, Inc., Medline Industries, LP, Medprin Biotech GmbH, Medtronic PLC, Meril Life Sciences Pvt. Ltd., Olympus Corporation, Pfizer Inc., Rousselot BV by Darling Ingredients International Holding B.V., Royal DSM, Shilpa Medicare Limited, Stapleline Medizintechnik GmbH, Stryker Corporation, SYMATESE, Teleflex Incorporated, Terumo Corporation, Zhejiang Perfectseal New Material Technology Co., Ltd., and Zimmer Biomet Holdings, Inc..

This research report categorizes the Hemostats Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Type
  • Collagen-Based Hemostats
  • Combination Hemostats
  • Gelatin-Based Hemostats
  • Oxidized Regenerated Cellulose-Based Hemostats
  • Thrombin-Based Hemostats
• Formulation
  • Matrix & Gel Hemostats
  • Powder Hemostats
  • Sheet & Pad Hemostats
  • Sponge Hemostats
• Application
  • Cardiovascular Surgery
  • General Surgery
  • Gynecological Surgery
  • Neurological Surgery
  • Orthopedic Surgery
  • Reconstructive Surgery

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

1. What is the market size and forecast of the Hemostats Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Hemostats Market?
3. What are the technology trends and regulatory frameworks in the Hemostats Market?
4. What is the market share of the leading vendors in the Hemostats Market?
5. Which modes and strategic moves are suitable for entering the Hemostats Market?